Recently, overexpression of the anti-apoptotic protein BCL2 has been observed in select ETP-ALL cases, suggesting that BCL2 inhibition using venetoclax may represent a viable therapeutic option. Here, BCL2 is linked to acute lymphoblastic leukemia.